HLX22

Home
Ligands
HLX22

GtoPdb Ligand ID: 13443

Comment: HLX22 is a humanized anti-HER2 (EGFR2; ERBB2) IgG1 monoclonal antibody. It binds within the same HER2 subdomain as trastuzumab, but at a separate, non-overlapping epitope [1]. HLX22 is proposed to offer synergistic antitumour efficacy in combination with trastuzumab/trastuzumab biosimilars.

References
1. Wei R, Zhang W, Yang F, Li Q, Wang Q, Liu N, Zhu J, Shan Y. (2024) Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer. J Transl Med, 22 (1): 641. [PMID:38982548]
2. Zhu X, Ding Y, Wang Q, Yang G, Zhou L, Wang Q. (2023) HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial. Invest New Drugs, 41 (3): 473-482. [PMID:37140695]

References

1. Wei R, Zhang W, Yang F, Li Q, Wang Q, Liu N, Zhu J, Shan Y. (2024)
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer.
J Transl Med, 22 (1): 641. [PMID:38982548]

2. Zhu X, Ding Y, Wang Q, Yang G, Zhou L, Wang Q. (2023)
HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial.
Invest New Drugs, 41 (3): 473-482. [PMID:37140695]